Whitehawk Therapeutics (WHWK) director granted options on 38,040 shares

Rhea-AI Filing Summary

Whitehawk Therapeutics director Caley Castelein received a new stock option grant covering 38,040 shares of common stock. The option has an exercise price of $4.16 per share and expires on June 12, 2036. Following this grant, Castelein holds stock options for 38,040 underlying shares directly.

According to the award terms, all 38,040 option shares vest 100% if Castelein continues as a service provider until the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately prior to the next annual stockholder meeting after that grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Castelein Caley

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 38,040 shares Exercise price: $4.16 per share Expiration date: June 12, 2036 +3 more

6 metrics

Option shares granted 38,040 shares Stock option grant to director on June 12, 2026

Exercise price $4.16 per share Strike price of stock option award

Expiration date June 12, 2036 Option term end date

Underlying shares 38,040 shares Common stock underlying the option

Post-transaction option holdings 38,040 shares Total option shares held after grant

Vesting condition 100% cliff vesting Earlier of 1-year from June 12, 2026 or before next annual meeting

Key Terms

Stock Option (right to buy), 2021 Equity Incentive Plan, Service Provider, Date of Grant, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2021 Equity Incentive Plan financial

"defined in the Issuer's 2021 Equity Incentive Plan through such applicable date"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

Date of Grant financial

""Date of Grant" shall mean June 12, 2026."

annual meeting of stockholders financial

"prior to the next annual meeting of stockholders following the Date of Grant"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Castelein Caley

(Last) (First) (Middle)

C/O WHITEHAWK THERAPEUTICS, INC.

2 HEADQUARTERS PLAZA, EAST BUILDING, 11T

(Street)

MORRISTOWN NEW JERSEY 07960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Whitehawk Therapeutics (WHWK) director Caley Castelein report in this Form 4?

Caley Castelein reported receiving a stock option grant for 38,040 shares of Whitehawk Therapeutics common stock. The option was awarded as compensation, not purchased in the market, and represents a new derivative position directly held by the director.

How large is Caley Castelein’s stock option grant at Whitehawk Therapeutics (WHWK)?

The grant covers options on 38,040 shares of Whitehawk Therapeutics common stock. All 38,040 shares are tied to a single option award, and this amount also equals the total number of option shares Castelein holds after the reported transaction.

What is the exercise price and expiration date of the WHWK stock options granted to Castelein?

The options have an exercise price of $4.16 per share and expire on June 12, 2036. This means Castelein can buy Whitehawk Therapeutics common stock at $4.16 per share anytime before the June 12, 2036 expiration date, once the options are vested.

When do Caley Castelein’s Whitehawk Therapeutics (WHWK) options vest?

All 38,040 option shares vest 100% if Castelein remains a service provider through the vesting date. Vesting occurs on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately before the next annual stockholder meeting after that date.

Is this WHWK Form 4 a market purchase or a compensation award?

This Form 4 reflects a compensation-related stock option award, not a market purchase. The transaction code is “A” for grant, award, or other acquisition, and the price per option at grant is reported as $0.00, consistent with an equity incentive grant.

Does Caley Castelein hold the WHWK options directly or through an entity?

The filing shows the options are held directly by Castelein. The ownership code is “D” for direct ownership, and there is no footnote indicating that the options are held through a trust, LLC, or other indirect entity on Castelein’s behalf.